Concord Biotech Limited has informed the Exchange about Transcript
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Concord Biotech reported FY25 revenue of INR 1,200 crores, up 18% YoY, with Q4 revenue at INR 430 crores, a 35% jump. PAT for the year grew 21% to INR 372 crores, while EBITDA margin held at 42.2%. API segment contributed 78% of revenue at INR 940 crores (+14%), while formulations grew 38% to INR 260 crores. The Board recommended a final dividend of INR 10.7 per share. Key milestones include commissioning of a new injectable facility at Valthera, ANDA approval for Teriflunomide tablets in the US, and the launch of the company's first commercial CDMO project with an innovator partner. Management also highlighted a long-term revenue CAGR target of 25%, supported by the injectable unit's potential to generate INR 600 crores in turnover and ongoing CDMO deals.
Strong FY25 performance with healthy margin retention and a robust growth pipeline signals positive momentum for shareholders. The newly commissioned injectable facility, expanding CDMO business, and diversified product portfolio provide multiple growth levers, though the company flagged some gross margin pressure from a changing product mix. Overall, the transcript reinforces a positive earnings outlook without major negatives.